MBrace has initiated an early clinical development trial (called Phase 1) to evaluate the safety, tolerability, and preliminary efficacy of MBRC-101, an antibody-drug conjugate, in patients with non-small cell lung cancer, breast cancer and other solid tumors. As the risks and benefits have not yet been adequately assessed, we are unable to provide investigational drug for expanded access or compassionate use. The most appropriate way for patients to access our investigational drug is by participating in our clinical trial, and we encourage you to speak with your doctor about whether you would qualify. Information regarding ongoing clinical trials can be accessed at www.clinicaltrials.gov. If you have additional questions about our expanded access policy, please contact clinicalsupport@mbracetrx.com.

In addition, any policies posted by MBrace shall not serve as a guarantee of access to any specific investigational therapy by any individual patient. MBrace will update this policy and its website as more clinical information becomes available on its investigational medicines.